Medicare moves to pay for stroke thrombolytic therapy

Article

Hospitals will no longer lose money for thrombolizing stroke patients with tissue plasminogen activator (tPA).

Hospitals will no longer lose money for thrombolizing stroke patients with tissue plasminogen activator (tPA).

In midsummer, the Centers for Medicare and Medicaid Services unveiled DRG 559, a new code that pays $11,578 per case of acute ischemic stroke treated with a thrombolytic. Hospitals had previously been paid a flat rate of about $4000 to $6000 per case, regardless of whether thrombolytics were used.

"We have been barely breaking even for some time here," said Dr. Kieran Murphy, director of interventional neuroradiology at Johns Hopkins University. "Even though we have an excellent program in place that allows us to treat these patients appropriately, we've had to be very cautious, trying to lose as little money as possible."

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.